Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | ALK F1174L |
| Therapy | Crizotinib + SHP099 |
| Indication/Tumor Type | neuroblastoma |
| Response Type | sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| ALK F1174L | neuroblastoma | sensitive | Crizotinib + SHP099 | Preclinical - Cell culture | Actionable | In a preclinical study, treatment with the combination of SHP099 and Xalkori (crizotinib) synergistically decreased viability of neuroblastoma cell lines harboring ALK F1174L in culture (PMID: 38032104). | 38032104 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (38032104) | SHP2 inhibition with TNO155 increases efficacy and overcomes resistance of ALK inhibitors in neuroblastoma. | Full reference... |